MedTrace Logo

CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)

NCT02827890 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-08-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate a pharmacokinetic drug interaction between sitagliptin and lobeglitazone in healthy male volunteers.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

Januvia Tab. 100mg

Januvia Tab. 100mg\*1T/day for 5days, QD, PO

DRUG

Januvia Tab. 100mg + Duvie Tab. 0.5mg

Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Min-Gul Kim, MD,PhD · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-04-30
Completion
2016-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02827890 on ClinicalTrials.gov